Jiangxi Boya Bio-Pharmaceutical Disputes Responsibility In Drug Deaths
This article was originally published in PharmAsia News
Executive Summary
China's State FDA is overseeing the investigation of six deaths last month caused by the human immunoglobulin manufactured by Jiangxi Boya Bio-Pharmaceutical. The drug maker, which obtained China's GMP authentication in 1998, has identified the drug batch in the incident. To date, 9,575 doses of the batch were sold, of which 3,192 had been used and the rest recalled. The company asserts that the drug's production process is in order and it has not received any notice from the authorities to stop production. It also stresses the stringent requirements for storing such a perishable product and is confident there is no issue of expiry. The Jiangxi province police are investigating whether any law-breaking activities happened in the distribution chain. (Click here for more - Chinese Language)
You may also be interested in...
Lethal Drug Manufacturer Resumes Production And Sales
Jiangxi Boya Bio-pharmaceutical, the manufacturer of the human immunoglobulin that caused six deaths last May (PharmAsia News, Jun. 9, 2008), has resumed its drug production and sales. Company inside sources confirmed that the product has been selling for some time, but only for wholesale business due to very small production output. An official at Jiangxi FDA revealed he has received information that Boya is not linked to the deaths but no formal report has been released. However, a State FDA spokesman stressed that the agency has not issued any such statement. (Click here for more - Chinese Language)
China’s SFDA Rapid Response To Biopharmaceutical-Triggered Deaths Seen As Progress By Industry Observers
BEIJING - In a case that closely parallels FDA's investigation of the drug heparin, China's State FDA is now examining a biopharmaceutical that triggered severe adverse reactions in seven Chinese patients, six of whom have died
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”